Format

Send to

Choose Destination
J Nucl Med. 2015 Sep;56(9):1458-64. doi: 10.2967/jnumed.115.158337. Epub 2015 Jul 23.

β-Radioluminescence Imaging: A Comparative Evaluation with Cerenkov Luminescence Imaging.

Author information

1
Department of Radiation Oncology, Stanford University, Stanford, California mtking12@gmail.com.
2
Department of Radiation Oncology, Stanford University, Stanford, California.
3
College of Pharmacy, Oregon State University, Portland, Oregon.
4
Department of Radiology, Stanford University, Stanford, California Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China; and.
5
Department of Otolaryngology, Stanford University, Stanford, California.
6
Department of Radiology, Stanford University, Stanford, California.

Abstract

Cerenkov luminescence imaging (CLI) can provide high-resolution images of (18)F-FDG-avid tumors but requires prolonged acquisition times because of low photon sensitivity. In this study, we proposed a new modality, termed β-radioluminescence imaging (β-RLI), which incorporates a scintillator with a γ-rejection strategy for imaging β particles. We performed a comparative evaluation of β-RLI with CLI in both in vitro and in vivo systems.

METHODS:

Using in vitro phantoms, we characterized the photon sensitivity and resolution of CLI and β-RLI. We also conducted a series of in vivo experiments with xenograft mouse models using both amelanotic (A375, UMSCC1-Luc) and melanotic (B16F10-Luc) cell lines. The B16F10 and UMSCC1 cell lines were transfected with the luciferase gene (Luc). CLI was acquired over 300 s, and β-RLI was acquired using two 10-s acquisitions. We correlated (18)F -: FDG activities, as assessed by PET, with tumor radiances for both β-RLI and CLI. We also compared tumor signal-to-background ratios (SBRs) between these modalities for amelanotic and melanotic tumors.

RESULTS:

For in vitro experiments, the photon sensitivity for β-RLI was 560-fold greater than that for CLI. However, the spatial resolution for β-RLI (4.4 mm) was inferior to that of CLI (1.0 mm). For in vivo experiments, correlations between (18)F-FDG activity and tumor radiance were 0.52 (P < 0.01) for β-RLI, 0.81 (P = 0.01) for amelanotic lesions with CLI, and -0.08 (negative contrast; P = 0.80) for melanotic lesions with CLI. Nine of 13 melanotic lesions had an SBR less than 1 for CLI, despite an SBR greater than 1 among all lesions for β-RLI.

CONCLUSION:

β-RLI can produce functional images of both amelanotic and melanotic tumors in a shorter time frame than CLI. Further engineering developments are needed to realize the full clinical potential of this modality.

KEYWORDS:

Cerenkov; beta; melanoma; radioluminescence; surgery

PMID:
26205301
DOI:
10.2967/jnumed.115.158337
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center